Ipsen Sa · EURONEXT:IPN
Ipsen Sa — J.P. Morgan Healthcare Conference 2025
30 slides from Ipsen Sa's conference presentation, January 2025
Slide 1: Investor Presentation
Investor Presentation J.P. Morgan Healthcare Conference January 2025
Slide 2: Forward-looking statements
Forward-looking statements This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements
Slide 3: Our strategy
Our strategy Bringing Building full potential of high-value innovative medicines Focus. sustainable pipeline to patients Together. For patients & society Delivering Boosting efficiencies to enable culture of investments & collaboration, support growth excellence & impact on patients & society 3
Slide 4: Our growth journey
Our growth journey Next phase of transformation built on solid foundations 2028+ Lasting momentum 2024-2027 Balanced & diversified Dynamic growth portfolio across three therapeutic areas 2020-2023 Multiple launches Sustained growth Setting foundations though pipeline delivery & external innovation N
Slide 5: Our increasingly diversified portfolio
Our increasingly diversified portfolio Seven medicines with potential sales of ≥€500m each by 2027 Seven medicines: potential sales ≥€500m each 2027+ Four medicines: sales ≥€500m each 2023 One medicine: sales ≥€500m 2020 5
Slide 6: Our current performance and 2027 outlook
Our current performance and 2027 outlook September YTD 2024 sales: +9.2%1 TOTAL-SALES: CORE OPERATING PRIORITY FOR CAPITAL CAGR 2023-2027 MARGIN 2027 ALLOCATION FOR EXTERNAL INNOVATION up to ≥+7% ≥32% €5bn 1 of total sales of cumulative firepower by 20272 CAGR: compound annual growth rate. Excluding
Slide 7: Ipsen's investment case
Ipsen’s investment case External Focus on Global Expanding innovation Specialty Care footprint pipeline strategy Opportunities for Well-balanced 6 pivotal readouts by 35+ assets added further growth across geographical presence 2026 with a mix of since 2020 across the 3 therapeutic areas with medici
Slide 8: Ipsen's investment case
Ipsen’s investment case External Focus on Global Expanding innovation Specialty Care footprint pipeline strategy Opportunities for Well-balanced 6 pivotal readout by 35+ assets added further growth across geographical presence 2026 with good mix of since 2020 across stage the 3 therapeutic areas wit
Slide 9: Growing our Oncology portfolio
Focus on Specialty Care Growing our Oncology portfolio Global peak sales €m / direction Neuroendocrine Erosion tumors (NET) Metastatic prostate Mid-single 73% cancer (mCRPC) digit growth 2 of total sales1 Renal cell carcinoma Peak sales (RCC) 5 >€700m 3 Metastatic pancreatic Peak sales cancer (mPDAC
Slide 10: Building a Rare Disease franchise
Focus on Specialty Care Building a Rare Disease franchise Global peak sales €m Rare cholestatic-liver Peak sales diseases >€700m 2 5% (PFIC, ALGS, BA) Primary Biliary of total sales1 Peak sales Cholangitis >€500m 3 (PBC) Fibrodysplasia Ossificans Peak sales Progressive >€100m (FOP) High unmet needs
Slide 11: Leading in Neurotoxins
Focus on Specialty Care Leading in Neurotoxins Attractive market growth in Tx & Ax, returning to pre-pandemic levels Significant barriers to entry 22% of total sales1 Investment in manufacturing capacity at Wrexham to meet market-growth potential & demand Dysport potential to deliver high-single dig
Slide 12: Ipsen's investment case
Ipsen’s investment case External Focus on Global Expanding innovation Specialty Care footprint pipeline strategy Opportunities for Well-balanced 6 pivotal readout by 35+ assets added further growth across geographical presence 2026 with good mix of since 2020 across stage the 3 therapeutic areas wit
Slide 13: Global leader with growth across all regions
Global footprint Global leader with growth across all regions North America Europe Rest of World 33% 40% 27% of total sales1 of total sales1 of total sales1 Leveraging platform through Sustained growth driven by Multiple opportunities in multiple launches Dysport & Cabometyx Asia-Pacific & Latin Ame
Slide 14: Ipsen's investment case
Ipsen’s investment case External Focus on Global Expanding innovation Specialty Care footprint pipeline strategy Opportunities for Well-balanced 6 pivotal readout by 35+ assets added further growth across geographical presence 2026 with good mix of since 2020 across stage the 3 therapeutic areas wit
Slide 15: Growing pipeline across three therapeutic areas
Expanding pipeline Growing pipeline across three therapeutic areas Phase I Phase II Phase III Registration Cabometyx: CABINET 2L+ pNET & epNET Tazverik + R2: SYMPHONY-1 2L FL Tovorafenib: FIREFLY-2* 1L pLGG Tovorafenib: FIREFLY-1* R/R pLGG IPN01194 Solid tumors Bylvay: BOLD Biliary atresia Iqirvo: E
Slide 16: Major upcoming pipeline milestones
Expanding pipeline Major upcoming pipeline milestones Medicine 2025 2026 Cabometyx (CABINET) 2L+ pNET & epNET Tovorafenib (FIREFLY-11) R/R pLGG Fidrisertib (FALKON) FOP, Phase IIb2 Bylvay (BOLD) BA, Phase III Iqirvo (ELSPIRE) PBC, Phase III Dysport (C-BEOND) CM, Phase III Dysport (E-BEOND) EM, Phase
Slide 17: Expanding Iqirvo's potential in PBC and beyond
Expanding pipeline Expanding Iqirvo’s potential in PBC and beyond Opportunity in wider patient population ELSPIRE: Global Phase III, randomized, double-blind, placebo-controlled trial Patients classified as partially controlled on 1L with ALP 1-1.67 but remain symptomatic1 Ipsen’s rare liver franchi
Slide 18: Long-acting neurotoxin
Expanding pipeline Long-acting neurotoxin Therapeutic & aesthetic evaluation Evaluating safety & efficacy in ongoing Phase II, multi-center trials – LANTIC: upper-facial lines (UFL) – LANTIMA: adult upper-limb spasticity (AUL) – MERANTI: chronic & episodic migraine – Dose escalation & dose-finding t
Slide 19: Ipsen's investment case
Ipsen’s investment case External Focus on Global Expanding innovation Specialty Care footprint pipeline strategy Opportunities for Well-balanced 6 pivotal readout by 35+ assets added further growth across geographical presence 2026 with good mix of since 2020 across stage the 3 therapeutic areas wit
Slide 20: External Innovation
External- innovation strategy External Innovation Six deals completed in 2024 Early-stage Late-stage Global licensing Strategic License & Global licensing Global licensing in Ex-U.S. licensing in oncology collaboration R&D collaboration in oncology immuno-oncology in pediatric in neuroscience in onc
Slide 21: Conclusion
Conclusion Strong momentum to deliver on 2027 objectives Top-line momentum driven by growth across therapeutic areas Several near-term pipeline opportunities & external innovation ambition Excellence in execution & commitment to sustainability Mathilde Senior Scientist, R&D Les Ulis,21France
Slide 22: Questions
QUESTIONS
Slide 23: Appendix
APPENDIX SIPSEN
Slide 24: Oncology
Oncology Key ongoing clinical-trial highlights PRIMARY TRIAL INDICATION PATIENTS DESIGN STATUS ENDPOINT(S) Primary endpoint met Tovorafenib FIREFLY-1 R/R pLGG 140 Tovorafenib ORR & safety Anticipated Phase II regulatory submission NCT04775485 2025 Tovorafenib Tovorafenib FIREFLY-2 1L pLGG 400 or ORR
Slide 25: Oncology
Oncology Key ongoing clinical-trial highlights PRIMARY TRIAL INDICATION PATIENTS DESIGN STATUS ENDPOINT(S) R/R FL: following at least one prior Tazverik systemic Tazverik + R2 SYMPHONY-1 chemotherapeutic, 612 or PFS Recruiting1 Phase III immunotherapeuti placebo + R2 NCT04224493 c, or chemo- immunot
Slide 26: Rare Disease
Rare Disease Key ongoing clinical-trial highlights PRIMARY TRIAL INDICATION PATIENTS DESIGN STATUS ENDPOINT Iqirvo Placebo ELMWOOD PSC 68 or Safety and tolerability Fully recruited1 Phase II Iqirvo NCT05627362 Iqirvo Placebo ELSPIRE2 2L PBC 72 or Normalisation of ALP Recruiting1 Phase III Iqirvo NCT
Slide 27: Rare Disease
Rare Disease Key ongoing clinical-trial highlights PRIMARY TRIAL INDICATION PATIENTS DESIGN STATUS ENDPOINT(S) Bylvay Placebo BOLD Time to first occurrence of Biliary atresia 254 or Fully recruited1 Phase III liver transplant, or death Bylvay NCT04336722 Fidrisertib Placebo or FALKON* FOP two dosing
Slide 28: Neuroscience
Neuroscience Key ongoing clinical-trial highlights PRIMARY TRIAL POPULATION PATIENTS DESIGN STATUS ENDPOINT IPN10200 Ax Dose escalation & dose- LANTIC Moderate to severe 727 finding versus Safety Recruiting1 Phase II upper facial lines Dysport or placebo NCT04821089 IPN10200 Tx Dose escalation & dos
Slide 29: Investor Relations
Investor Relations Alina Levchuk Nicolas Bogler Vice President Senior Manager Investor Relations Investor Relations +41 79 572 8712 +33 6 52 19 98 92 alina.levchuk@ipsen.com nicolas.bogler@ipsen.com 29
Slide 30: Thank you
Thank you Follow us: www.ipsen.com